Provectus Pharmaceuticals Inc. (PVCT.OB) Initiates Phase 1 Trial of Liver Cancer Drug
Source: http://Blog.QualityStocks.net/?p=18212Posted on Thursday, October 1st, 2009 | In Investing Lessons, Small & Micro Cap
Provectus Pharmaceuticals Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of their drug – PV-10 – for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. The same drug is currently undergoing Phase 2 study for metastatic melanoma.
The primary objective of the open-label study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with liver cancer. Additional objectives are to assess the distribution and retention of PV-10 in the injected lesion, tumor response and viability, and plasma pharmacokinetics of the drug following intralesional injection.
The CEO of Provectus, Dr. Craig Dees, PhD, spoke about the Phase 1 trial, “We hope to demonstrate that PV-10, which has shown excellent selectivity for melanoma, will be a viable therapeutic for liver cancer and cancers metastatic to the liver.”
The company’s leading oncology drug, PV-10, is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly 30 years by ophthalmologists to assess damage to the eye. It has also been used as an intravenous diagnostic to detect liver ailments. Rose Bengal has an established safety history, a short half-life in the bloodstream, and is excreted via the liver and kidneys.
Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer cells via a process called chemoablation whereby cancer cells undergo a form of cell death that mimics both features of necrosis and apoptosis. PV-10 does this without damaging surrounding healthy tissue, significantly reducing systemic side effects.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Some Options as the US Dollar Continues its Slide - November 24th, 2009
- Newport Digital Technologies (NPDT.OB) Has a Competitive Edge - November 24th, 2009
- Small Cap Voice Featured Company: DecisionPoint Systems, Inc. (DNPI.OB) - November 24th, 2009
- Small Cap Voice Featured Company: Hitor Group, Inc. (HITR.OB) - November 24th, 2009
- Novavax, Inc. (NVAX) Prices Offering Of Common Stock - November 24th, 2009
apoptosis, cancer, Cancers, ceo, Craig Dees, dermatology biopharmaceutical, Investing Lessons, Liver Cancer, Melanoma, necrosis, pharmacokinetics, Provectus Pharmaceuticals Inc., PV-10, Rose Bengal, Small & Micro Cap, tumor
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.